146 related articles for article (PubMed ID: 24731275)
1. Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.
Arnatt CK; Adams JL; Zhang Z; Haney KM; Li G; Zhang Y
Bioorg Med Chem Lett; 2014 May; 24(10):2319-23. PubMed ID: 24731275
[TBL] [Abstract][Full Text] [Related]
2. Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents.
Arnatt CK; Zaidi SA; Zhang Z; Li G; Richardson AC; Ware JL; Zhang Y
Eur J Med Chem; 2013 Nov; 69():647-58. PubMed ID: 24095757
[TBL] [Abstract][Full Text] [Related]
3. Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.
Xu GG; Zaidi SA; Zhang F; Singh S; Raborg TJ; Yuan Y; Zhang Y
Bioorg Med Chem Lett; 2015 Sep; 25(17):3721-5. PubMed ID: 26096680
[TBL] [Abstract][Full Text] [Related]
4. The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents.
Haney KM; Zhang F; Arnatt CK; Yuan Y; Li G; Ware JL; Gewirtz DA; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5159-63. PubMed ID: 21820898
[TBL] [Abstract][Full Text] [Related]
5. Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.
Zhang F; Arnatt CK; Haney KM; Fang HC; Bajacan JE; Richardson AC; Ware JL; Zhang Y
Eur J Med Chem; 2012 Sep; 55():395-408. PubMed ID: 22901310
[TBL] [Abstract][Full Text] [Related]
6. Forward- and reverse-synthesis of piperazinopiperidine amide analogs: a general access to structurally diverse 4-piperazinopiperidine-based CCR5 antagonists.
Feng DZ; Song YL; Jiang XH; Chen L; Long YQ
Org Biomol Chem; 2007 Aug; 5(16):2690-7. PubMed ID: 18019544
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines.
Chen H; Xu F; Liang X; Xu BB; Yang ZL; He XL; Huang BY; Yuan M
Bioorg Med Chem Lett; 2015 Jan; 25(2):285-7. PubMed ID: 25488843
[TBL] [Abstract][Full Text] [Related]
8. Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents.
Zhang X; Haney KM; Richardson AC; Wilson E; Gewirtz DA; Ware JL; Zehner ZE; Zhang Y
Bioorg Med Chem Lett; 2010 Aug; 20(15):4627-30. PubMed ID: 20579875
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric synthesis of (-)-brevipolide H through cyclopropanation of the α,β-unsaturated ketone.
Lin JW; Kurniawan YD; Chang WJ; Leu WJ; Chan SH; Hou DR
Org Lett; 2014 Oct; 16(20):5328-31. PubMed ID: 25275479
[TBL] [Abstract][Full Text] [Related]
10. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element.
Tagat JR; McCombie SW; Steensma RW; Lin S; Nazareno DV; Baroudy B; Vantuno N; Xu S; Liu J
Bioorg Med Chem Lett; 2001 Aug; 11(16):2143-6. PubMed ID: 11514156
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents.
Fiorino F; Magli E; Perissutti E; Severino B; Frecentese F; Esposito A; De Angelis F; Incisivo GM; Massarelli P; Nencini C; Di Gennaro E; Budillon A; Di Cintio A; Santagada V; Caliendo G
Eur J Med Chem; 2011 Jun; 46(6):2206-16. PubMed ID: 21440338
[TBL] [Abstract][Full Text] [Related]
12. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
Debnath AK
J Med Chem; 2003 Oct; 46(21):4501-15. PubMed ID: 14521412
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
Jia JM; Liu F; Xu XL; Guo XK; Jiang F; Cherfaoui B; Sun HP; You QD
Bioorg Med Chem Lett; 2014 Mar; 24(6):1557-61. PubMed ID: 24582477
[TBL] [Abstract][Full Text] [Related]
14. Highly functionalized 2-oxopiperazine-based peptidomimetics: an approach to PAR1 antagonists.
Valdivielso ÁM; Ventosa-Andrés P; Tato F; Fernández-Ibañez MÁ; Pappos I; Tsopanoglou NE; García-López MT; Gutiérrez-Rodríguez M; Herranz R
Eur J Med Chem; 2013; 70():199-224. PubMed ID: 24158013
[TBL] [Abstract][Full Text] [Related]
15. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
Peng P; Chen H; Zhu Y; Wang Z; Li J; Luo RH; Wang J; Chen L; Yang LM; Jiang H; Xie X; Wu B; Zheng YT; Liu H
J Med Chem; 2018 Nov; 61(21):9621-9636. PubMed ID: 30234300
[TBL] [Abstract][Full Text] [Related]
17. Novel 1-(2-aryl-2-adamantyl)piperazine derivatives with antiproliferative activity.
Fytas C; Zoidis G; Tsotinis A; Fytas G; Khan MA; Akhtar S; Rahman KM; Thurston DE
Eur J Med Chem; 2015 Mar; 93():281-90. PubMed ID: 25703296
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
20. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.
Sicoli D; Jiao X; Ju X; Velasco-Velazquez M; Ertel A; Addya S; Li Z; Andò S; Fatatis A; Paudyal B; Cristofanilli M; Thakur ML; Lisanti MP; Pestell RG
Cancer Res; 2014 Dec; 74(23):7103-14. PubMed ID: 25452256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
